2007: Late-Breaking Posters
Search
or
Browse by Day
Late-Breaking Posters
L1
Milnacipran Efficacy in the Treatment of Fibromyalgia Syndrome: A 15-Week, Randomized, Double-Blind, Placebo-Controlled Trial
L2
Placebo-Controlled Pilot Study of Rilonacept (IL-1 Trap), A Long Acting IL-1 Inhibitor, In Refractory Chronic Active Gouty Arthritis
L4
Intra-articular Botulinum Toxin Type A (IA-BoNT/A) Significantly Decreases Shoulder Pain in Patients with Refractory Shoulder Pain due to Osteoarthritis: A Randomized Double-Blind Placebo-Controlled Trial
L5
Increase in vertebral fracture risk In postmenopausal women using Omeprazole.
L6
Targeted Inhibition of IL-6 Signalling withTocilizumab Improves Quality of Life and Function in Patients with Rheumatoid Arthritis with Inadequate Response to a Range of DMARDs
L7
TRU-015 Improves Rheumatoid Arthritis Disease Activity in a Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase 2 Dose Ranging Trial
L8
Predictors of Increased Carotid Intima Medial Thickness (CIMT) in the Atherosclerosis Prevention in Pediatric Lupus Erythematosus (APPLE) Cohort
L9
Elevated Antiangiogenic Factors Predict Preeclampsia In Pregnant Patients With SLE And/Or APL Antibodies
L10
Golimumab, a New, Human, TNF-alpha Antibody Administered as a Monthly Subcutaneous Injection in Ankylosing Spondylitis (AS): 24-Week Efficacy and Safety Results of the Randomized, Placebo-Controlled GO-RAISE Study
L11
A Randomised Controlled Trial of Infliximab shows clinical and MRI efficacy in patients with HLA B27 positive very early ankylosing spondylitis
L12
A Multi-center Crossover Study of MQX-503, a Topical Formulation of Nitroglycerin, in Patients with Raynaud’s Phenomenon
See more of:
Late-Breaking Abstracts Poster Sessions
<< Previous Session Level
|
Next Session Level >>